http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
임유진,이상명,김동수,김준범,최광식,이신혜,박정규,이동운,Lim, Eu-Gene,Lee, Sang-Myeong,Kim, Dong-Soo,Kim, Joon-Bum,Lee, Shin-Hye,Choi, Kwang-Sik,Park, Chung-Gyoo,Lee, Dong-Woon 한국응용곤충학회 2012 한국응용곤충학회지 Vol.51 No.1
솔껍질깍지벌레는 우리나라 곰솔림의 주요한 해충의 하나이다. 본 연구는 우리나라에서 솔껍질깍지벌레의 분포를 알아보기 위하여 7개도 3개 광역시, 91개 시군구, 686 읍면동의 해송림에서 2010년 밀도를 조사하였다. 5개도 2개 광역시에서 솔껍질깍지벌레가 서식하고 있었는데 시군구별로는 조사대상의 64.8%인 59개 시군구에서 서식이 확인되었다. 솔껍질깍지벌레의 분포는 남해안 전역과 동해안의 포항, 서해안의 충남 보령지역까지 분포하였다. 충북과 대전광역시 및 제주도에서는 솔껍질깍지벌레의 분포가 확인되지 않았다. 부산지역은 16곳의 모든 구에서 솔껍질깍지벌레가 분포하였고, 시군 단위에서는 전남 해남군의 솔껍질깍지벌레 평균밀도가 1.713마리/0.785 $cm^2$로 가장 높았으며 읍면동 단위에서는 해남군 송지면이 6.36마리/0.785 $cm^2$로 가장 높았다. 곰솔 가지 내의 솔껍질깍지벌레 밀도와 솔껍질깍지벌레가 서식하고 있는 빈도와는 높은 상관관계가 있었다(상관계수=0.89). The black pine bast scale, $Masucoccus$ $thunbergianae$ (Hemiptera: Margarodidae), is a serious pest of the Japanese black pine, $Pinus$ $thunbergii$, in Korea. The distribution of the black pine bast scale was examined, looking overall at 686 towns (eup), townships (myeon) or neighborhoods (dong). There were Japanese black pine ($Pinus$ $thunbergii$) forests in 91 cities, counties (gun) and borough (gu), in seven provinces and three metropolitan cities during 2010. Black pine bast scale were found in 64.8% of cities or counties or borough (59) in 7 provinces and 3 metropolitan cities, and were distributed in all South Costal regions, Pohang in East Costal region and Boryeong in West Costal region. Chungcheongbukdo, Daejeon and Jeju did not have black pine bast scale. All the gu regions in Busan had black pine bast scale, of which the area with the highest prevalence was Haenam in Jeollanamdo (1.713 crawlers/0.785 $cm^2$). Songji-myeon had the highest occurrence rate (6.36 crawlers/0.785 $cm^2$) from the towns, township and dong. The density of black pine bast scale in twigs was highly correlated with percentage of the sample with scale (Correlation coefficacy=0.89).
Park, Jinbong,Jeon, Yong-Deok,Kim, Hye-Lin,Lim, Hara,Jung, Yunu,Youn, Dong-Hyun,Jeong, Mi-Young,Kim, Hyun-Ju,Kim, Sung-Hoon,Kim, Su-Jin,Hong, Seung-Heon,Um, Jae-Young Hindawi Publishing Corporation 2013 Evidence-based Complementary and Alternative Medic Vol.2013 No.-
<P>Obesity has become a major health threat in developed countries. However, current medications for obesity are limited because of their adverse effects. Interest in natural products for the treatment of obesity is thus rapidly growing. Korean Medicine (KM) is characterized by the wide use of herbal formulas. However, the combination rule of herbal formulas in KM lacks experimental evidence. According to <I>Shennong's Classic of Materia Medica</I>, the earliest book of herbal medicine, <I>Veratrum nigrum</I> (VN) has antagonistic features against <I>Panax ginseng</I> (PG), and the PG-VN pair is strictly forbidden. In this study, we have shown the effects of PG, VN, and their combination on obesity in high-fat (HF) diet-induced obese mice and in 3T3-L1 cells. PG, VN, and PG-VN combination significantly reduced weight gain and the fat pad weight in HF diet-induced obese mice. They also significantly decreased lipid accumulation and the expressions of two major adipogenesis factors, PPAR<I><I>γ</I></I> and C/EBP<I><I>α</I></I>, in 3T3-L1 cells. In addition, the PG-VN combination had synergistic effects compared with the mixture of extracts of PG and VN on inhibition of PPAR<I><I>γ</I></I> and C/EBP<I><I>α</I></I> expressions at lower doses. These results indicate a new potential anti-obese pharmacotherapy and also provide scientific evidence supporting the usage of herbal combinations instead of mixtures in KM.</P>
Lim, Myong Cheol,Lee, Dong Ock,Kang, Sokbom,Seo, Sang-Soo,Lee, Bo-Yon,Park, Sang-Yoon Parthenon Pub 2009 Gynecological endocrinology Vol.25 No.7
<P>OBJECTIVES: The symptoms associated with ovarian cancer are vague. Endometriosis, which causes dysmenorrhea and dyspareunia, is frequently detected along with ovarian clear cell carcinoma (OCCC). We have therefore evaluated the clinical manifestations of OCCC based on the co-existence of endometriosis. METHODS: A retrospective analysis was conducted on 43 patients who had been treated for OCCC at the National Cancer Center between June 2000 and July 2007. Using medical records and the cancer registry, the clinical features and laboratory findings were analysed. RESULTS: Endometriosis was identified in 16 (37.2%) of the 43 patients with OCCC. The main presenting symptoms included a hard, palpable mass (32.6%), and newly developed or an exacerbation of dysmenorrhea (32.6%) and dyspareunia (25.6%). Gastrointestinal symptoms, pelvic pain, and abdominal distension existed in nine (20.9%), eight (18.6%) and one (2.3%) of the patients, respectively. The symptoms did not differ statistically in patients with or without endometriosis. Thirty-seven percent (11/30) of the patients had a normal CA-125 level (<35 U/ml); 18.8% (3/16) of the patients without endometriosis and 57% (8/14) of the patients with endometriosis had normal levels of CA-125 (<35 U/ml). Nine of 16 (56.3%) patients with early stage OCCC had a normal CA-125 level. CONCLUSIONS: The main presenting symptoms in patients with OCCC include a hard, palpable mass, dysmenorrhea and dyspareunia, irrespective of co-existing endometriosis. A normal CA-125 level has limited value in excluding OCCC, especially in the early stages.</P>
( Dong Yeob Shin ),( Cheol Ryong Ku ),( Kyung Min Kim ),( Han Seok Choi ),( Yumie Rhee ),( Eun Jig Lee ),( Sung Kil Lim ) 대한내과학회 2012 The Korean Journal of Internal Medicine Vol.27 No.1
Bisphosphonates are potent inhibitors of bone resorption and widely used to treat osteoporosis. Extensive studies have shown that therapy with bisphosphonates improves bone density and decreases fracture risk. However, concerns have been raised about potential over-suppression of bone turnover during long-term use of bisphosphonates, resulting in increased susceptibility to and delayed healing of non-spinal fractures. We report a patient who sustained non-traumatic stress fractures in bilateral femoral shafts with delayed healing after long-term bisphosphonate therapy. She underwent open reduction and surgical internal fixation. Although bisphosphonates effectively prevent vertebral fractures, and their safety has been tested in randomized trials, we must emphasize the need for awareness of the possibility that long-term suppression of bone turnover with bisphosphonates may eventually lead to an accumulation of fatigue-induced damage and adverse skeletal effects such as delayed fracture healing.
Lim Sungsu,Shin Seulgi,Sung Yoonsik,Lee Ha Eun,Kim Kyu Hyeon,Song Ji Yeon,Lee Gwan-Ho,Aziz Hira,Lukianenko Nataliia,Kang Dong Min,Boesen Nicolette,Jeong Hyeanjeong,Abdildinova Aizhan,Lee Junghee,Yu By 생화학분자생물학회 2023 Experimental and molecular medicine Vol.55 No.-
Tau oligomers play critical roles in tau pathology and are responsible for neuronal cell death and transmitting the disease in the brain. Accordingly, preventing tau oligomerization has become an important therapeutic strategy to treat tauopathies, including Alzheimer’s disease. However, progress has been slow because detecting tau oligomers in the cellular context is difficult. Working toward tau-targeted drug discovery, our group has developed a tau-BiFC platform to monitor and quantify tau oligomerization. By using the tau-BiFC platform, we screened libraries with FDA-approved and passed phase I drugs and identified levosimendan as a potent anti-tau agent that inhibits tau oligomerization. 14C-isotope labeling of levosimendan revealed that levosimendan covalently bound to tau cysteines, directly inhibiting disulfide-linked tau oligomerization. In addition, levosimendan disassembles tau oligomers into monomers, rescuing neurons from aggregation states. In comparison, the well-known anti-tau agents methylene blue and LMTM failed to protect neurons from tau-mediated toxicity, generating high-molecular-weight tau oligomers. Levosimendan displayed robust potency against tau oligomerization and rescued cognitive declines induced by tauopathy in the TauP301L-BiFC mouse model. Our data present the potential of levosimendan as a disease-modifying drug for tauopathies.
Design and Characterization of the Integrated Matrix-Type SFCL
Dong-Chul Chung,Byung Hwa Yoo,Yong-sun Cho,Byung-Ik Jung,Hyo-Sang Choi,Tae-Hyun Sung,Young-Hee Han,Jong Ha Lee,Min Hwan Kwak,Sung Hun Lim,Byoung-Sung Han IEEE 2009 IEEE transactions on applied superconductivity Vol.19 No.3
<P>In this paper, we report the improved and integrated matrix-type superconducting fault current limiter (MFCL). The new MFCL proposed in this work has a structure that easily improves the quench characteristics of superconducting elements. This integrated MFCL is simply constructed by mounting a trigger element and superconducting elements in a single reactor, whereas older MFCL designs require several complex reactors for proper operation. Also this integrated type of structure provides a uniform and strong magnetic field with superconducting elements, compared with an old type MFCL. We designed and characterized the integrated MFCL with 1 times 3 superconducting modules and 2 times 3 superconducting modules. From experimental results, we confirmed that our integrated MFCL had advantages including a compact design, better quench characteristics and an easily adjustable increment of the capacity for fault current limiting.</P>
Lim, Kyoung Soo,Cho, Joo-Youn,Kim, Bo-Hyung,Kim, Jung-Ryul,Kim, Hwa-Sook,Kim, Dong-Kyu,Kim, Sung-Ho,Yim, Hyeon Joo,Lee, Sung-Hack,Shin, Sang-Goo,Jang, In-Jin,Yu, Kyung-Sang Blackwell Publishing Ltd 2009 British journal of clinical pharmacology Vol.68 No.6
<P><B>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT</B></P><P>• The importance of efficient drug development using biomarkers has been increasingly emphasized, from preclinical studies to clinical trials.</P><P>• However, as yet few ‘validated’ or ‘qualified’ biomarkers are used in early-stage drug development in terms of clinical pharmacology and disease pathophysiology.</P><P><B>WHAT THIS STUDY ADDS</B></P><P>• This first-time-in-human study provides evidence of the pharmacological activity of LC15-0444 in humans, by using dipeptidyl peptidase IV activity and active glucagon-like peptide-1 concentrations.</P><P>• LC15-0444 possesses pharmacokinetic and pharmacodynamic characteristics that support a once-daily dosing regimen.</P><P>AIMS</P><P>LC15-0444 is a selective and competitive inhibitor of dipeptidyl peptidase (DPP) IV with potential for the treatment of Type 2 diabetes. The aim was to investigate the pharmacokinetic (PK) and pharmacodynamic (PD) profiles after multiple oral ascending doses of LC15-0444 in healthy male subjects.</P><P>METHODS</P><P>A dose block-randomized, double-blind, placebo-controlled, parallel group study was performed in three groups with 10 subjects (eight for active drug; two for placebo) per group; each group received 200, 400 or 600 mg of LC15-0444 once daily for 10 days. Blood and urine samples were collected up to 24 h after the first dosing and up to 72 h after the last dosing.</P><P>RESULTS</P><P>The LC15-0444 concentration–time profiles exhibited characteristics of multicompartment disposition. No dose- or time-dependent change in PK parameters was observed. Mean elimination half-life was in a range 16.6–20.1 h in the dose groups. Mean renal clearance and fraction of unchanged drug excreted in urine was 18.6–21.9 and 0.40–0.48 l h<SUP>−1</SUP>, respectively. In the steady state, mean accumulation ratios by dose groups were between 1.22 and 1.31. More than 80% inhibition of DPP IV activity from baseline was sustained for >24 h in all dose groups.</P><P>CONCLUSIONS</P><P>This study provides evidence of the pharmacological activity of LC15-0444 in humans. LC15-0444 possesses PK and PD characteristics that support a once-daily dosing regimen.</P>